The impact of high dose oral cotrimoxazole in patients with COVID-19 with hypoxic respiratory failure requiring non-invasive ventilation: A Case Control Study

Saurabh Singh¹, Thomas John², Prashant Kumar¹, Syed Rehan Quadery³

¹ Department of Respiratory Medicine, IQ City Medical College Hospital, Durgapur, West Bengal, India.

² Department of Acute Medicine, Epsom and St Helier University Hospitals NHS Trust, London, UK

³ Department of Respiratory Medicine, Epsom and St Helier University Hospitals NHS Trust, London, UK

* Corresponding Author: Saurabh Singh, Assistant Professor, Department of Respiratory Medicine, IQ City Medical College Hospital, Durgapur, West Bengal, India. Email: saurabh.singh3108@icloud.com

Key Words: COVID-19, cytokine storm syndrome, hypoxic respiratory failure, non-invasive ventilation, cotrimoxazole, immunomodulation

Abstract (word count): 264 words

Main text (word count): 1745 words

Number of figures: 0

Number of tables: 2

Running head: Impact of Cotrimoxazole in patients with COVID-19 requiring NIV.

Funding: No funding was received.

Declaration of conflict of interest: None declared.

Author approval: All authors have seen and approved the manuscript.

Ethics: Ethical approval granted by the IQ City Medical College Hospital Institutional Ethics Committee.

Patient consent: No patient consent required as all data has been anonymized and no patient identifiable data included.

ABSTRACT

Background

COVID-19 can be fatal in a significant proportion of people who develop critical illness, resulting in hypoxic respiratory failure secondary to Acute Respiratory Distress Syndrome (ARDS) which is thought to be mediated by a cytokine storm syndrome. Steroids have been shown to be of some benefit, but the mainstay of treatment remains supportive.

Methods

The data was collected retrospectively from consecutive, newly diagnosed patients presenting to the critical care facility of I Q City Medical College Hospital, Durgapur, India between June and November 2020 with critical COVID-19 on non-invasive ventilation treated with high dose oral cotrimoxazole (CTX) in addition to standard therapy (ST) and compared with patients with critical COVID-19 receiving standard therapy alone.

Results

201 patients were identified. Of which 151 patients received CTX in addition to ST (mean age $\pm$ SD 59 ± 13 years, 81% male and mean BMI $\pm$ SD 28 ± 2) and 50 patients received ST alone (mean age $\pm$ SD 63 ± 12 , 64% male and mean BMI $\pm$ SD 27 ± 2). We observed that the patients with critical COVID-19 receiving CTX in addition to ST had significantly better outcomes including reduced in-patient mortality (13% versus 40%, $p < 0.001$), length of hospital and critical care unit stay (mean, 11 versus 15 days ($p < 0.001$) and 6 versus 11 days ($p < 0.001$) respectively), and the need for mechanical ventilation (16% versus 42%, $p < 0.001$) with improved CRP at day 7 (mean, 38mg/L versus 62mg/L, $p = 0.001$).

Conclusion

These results may be due to the antibiotic and anti-cytokine effects of CTX. Clinical trials are currently underway to test our observations.

Introduction

Over 10 million people in India have had confirmed Coronavirus Disease 19 (COVID-19), resulting in >150,000 deaths. The disease is self-limiting for the majority of those infected, but for those with critical disease steroids and supportive measures remains the mainstay of treatment.¹ Severity of the disease is related to various factors including male sex, obesity, ethnicity, diabetes and prior cardiac or respiratory diseases.²

A proportion of patients with severe COVID-19 mount an exaggerated immune response and react by producing an excess of cytokines.³ T- lymphocyte, monocyte and neutrophil activation as a result of this ‘cytokine storm’ leads to respiratory failure and acute respiratory distress syndrome (ARDS) requiring oxygen therapy and ventilatory support and is associated with higher mortality.^{4,5}

Viral pneumonias are known to predispose to secondary bacterial infections. Staphylococcus Aureus, MRSA and Stenotrophomonas maltophilia are the bacteria commonly seen in patients with Influenza A and in ventilated patients with SARS.^{6,7}

Co-trimoxazole (1:5, trimethoprim : sulphamethoxazole) is a bactericidal antibiotic used in the treatment of various infections.⁸ Methicillin sensitive Staphylococcus Aureus (MSSA), Methicillin resistant Staphylococcus Aureus (MRSA), Klebsiella pneumoniae, Haemophilus influenzae B and Stenotrophomonas maltophilia are some of the bacteria it is effective against.⁹

Cotrimoxazole also has effects upon the immune system, although not widely recognised.¹⁰

The cytokine storm may occur as a result of neutrophil recruitment to the lung due to the stimulation of the formyl peptide receptors (FPRs) by formyl peptides also known as Damage associated Molecular patterns which are released upon the mitochondrial injury of the host cells. FPRs are situated on the outside of the neutrophils and monocytes, and when stimulated

cause the release of intracellular and extracellular reactive oxygen series (ROS) which can drive the cytokine activation. In addition it stimulates the formation of Neutrophil Extracellular Traps (NETs) which block the alveolar capillary bed leading to significant hypoxaemia. Co-trimoxazole blocks the FPRs and can reduce the movement of neutrophils to the lung and NETosis. In addition sulphamethaxazole inhibits neutrophil activation by inhibiting Phorbol 12-myristate 13-acetate (PMA) stimulation thereby preventing Protein Kinase C activation and reducing inflammation.^{11,12} This offers a possible explanation for the observed clinical benefit by reducing neutrophil, monocyte and lymphocyte activation leading to a reduction in the risk of ARDS.¹²⁻¹⁷

Case reports describing clinical recovery from acute respiratory distress syndrome after the addition of cotrimoxazole are seen in medical literature.¹⁸ Recently more data has been published on the benefits of CTX in severe COVID-19.¹⁹⁻²²

We have treated nearly 700 patients with severe to critical COVID-19 with co-trimoxazole. Here we report our preliminary findings with the use of cotrimoxazole in the treatment of critical COVID-19, compared with a group of concurrent controls.

Methods

We retrospectively analysed data obtained from electronic case records and case notes of patients admitted to the critical care facility of the IQ City Medical College Hospital, Durgapur, West Bengal, India from 15th June 2020 to 15th November 2020 and followed up until discharge, death or the census date of 30th November 2020. Data was collected, anonymized and stored in a highly secure, password protected database.

Patients admitted with clinically suspected or confirmed COVID -19 were commenced on standard therapy including antibiotics (piperacillin/tazobactam and clarithromycin or azithromycin), dexamethasone, low molecular weight heparin, paracetamol, supplemental

oxygen therapy, intravenous fluids, antiviral drugs and other investigational therapies based on ICMR guidelines.²³ All the patients had Chest X rays and CT chest scan done on admission which confirmed lung infiltrates in a pattern consistent with a radiological diagnosis of COVID-19. All patients fitted the WHO criteria for critical COVID-19.²⁴

Cotrimoxazole is licensed for the treatment of respiratory infections and pneumonia. Patients diagnosed with COVID -19 (RT PCR or clinical) with increasing oxygen demands requiring non-invasive ventilation in the form of Continuous Positive Airway Pressure (CPAP) or High Flow Nasal Cannula (HFNC) were administered oral Cotrimoxazole (CTX; 160mg of trimethoprim and 800mg sulphamethoxazole) 8 hrly for 7 to 10 days in addition to standard therapy.⁸ This was agreed and approved by the physicians at the local respiratory departmental meeting held on the 15th of June 2020.

Consecutive cases of newly diagnosed critical COVID-19 receiving Cotrimoxazole in addition to standard therapy were included in the analysis. This group was matched 3:1 with concurrent controls (n=50) for age and disease severity (critical COVID-19).

Mortality, progression to mechanical ventilation, length of stay, improvements in CRP and Neutrophil-Lymphocyte Ratio (NLR) at Day 7 were the outcomes analysed.^{25,26}

Day 0 in the cases and controls was the day of admission to hospital.

Data on comorbidities previously suggested to be linked to higher risk of mortality in COVID-19 were also compared between the two groups.

Statistical Analysis

Continuous data are presented using mean and standard deviation. Comparisons between two groups of continuous data was made using the t-test for parametric and Mann Whitney U-test/Wilcoxon signed rank test for non-parametric data.

Categorical data was presented as number or percentage of patients. For categorical variables comparison between two groups was done using Chi-squared test or Fishers exact test (for small numbers). Prognostic variables were assessed using univariate and multivariate Cox regression analysis for survival. 27 variables in the whole cohort, case and control group were identified based on previous literature and entered into univariate Cox regression analysis.² Variables with a p-value of <0.20 at univariate analysis and < 10% missing data were included in the multivariate analysis using forward logistic regression method. A p-value of < 0.05 was considered to be significant. The statistical software SPSS was used for the analysis.

Ethics

Ethical approval was obtained from the IQ City Medical College Hospital Institutional Ethics Committee.

Results

Baseline characteristics:

Baseline characteristics from anonymized record reviews are shown in table 1 for standard therapy patients and those treated with the addition of CTX to standard therapy. Prior to 'Day 0' these patients had symptoms for a mean duration of 4 days in the CTX and control group. The groups were comparable for age, ethnic group, BMI, chronic lung disease, ischemic heart disease and Hypertension. Diabetes and chronic kidney disease were lower in the CTX added group at 39% and 2.7% respectively, compared with standard therapy alone at 60% and 18% respectively. Male sex was higher in the cotrimoxazole group at 81% compared to 64% in the standard therapy only group.

Baseline observations were similar for duration of symptoms, respiratory rate, body temperature, C- reactive protein and NLR (table 1). All patients required either CPAP or HFNC fulfilling the criteria for critical COVID-19.²⁴

Outcome:

87% of patients with added CTX were discharged well without oxygen after a mean length of hospital and critical care unit stay of 11 and 6 days respectively, 15% required mechanical ventilation, while 13% succumbed to the illness (table 2).

Data from the patients receiving standard therapy alone, showed that 60% of patients were discharged with a mean length of hospital and critical care unit stay of 15 and 11 days respectively, 42% required mechanical ventilation, while 40% died.

At day 7 patients in both groups showed a significant reduction in C-reactive protein levels compared to day 0, however the reduction was more pronounced in the CTX+ST group compared to the ST only group. In addition, patients with added CTX showed a significant improvement in NLR that was not seen in the group on standard therapy alone. (table 2).

None of the patients in the cotrimoxazole group experienced any side effects warranting stopping of the medication.

Prognostic indicators:

Univariate and multivariate analysis of the whole cohort, cotrimoxazole with ST and standard therapy only groups identified a number of predictors of outcome (supplementary table S1). In the ST only group male sex ($p = 0.191$), DM ($p=1.00$) and CKD ($p = 0.299$) did not predict survival at univariate analysis.

Discussion

To the best of our knowledge, this is the first study primarily focussing on pharmacological interventions in patients with COVID-19 on non-invasive ventilation. We have compared the baseline characteristics and clinical outcomes in patients who received high dose CTX in addition to ST with patients who received standard only, in a critical care setting.

In this study we have shown a significant reduction in mortality, intubation rate, length of hospital and critical care stay and inflammatory markers in the CTX+ST group compared to the ST only group in keeping with the study by Quadery and co-workers.¹⁹ The mortality and the rate of intubation in the ST only group was similar to that of current literature where patients with COVID 19 on non-invasive ventilation who were for further escalation was 47% and 57% respectively.²⁷

The higher dose cotrimoxazole used in our study is indicated in patients with nocardiasis with excellent safety profile.²⁸ This results in higher concentration of the trimethoprim in the blood which is a potent anti-inflammatory agent resulting in increased inactivation of neutrophils and monocytes in the blood, thus blocking the cytokine storm mediated ARDS.

While male sex, Diabetes & Chronic Kidney Disease were not matched between the CTX+ST and ST only group in this study, a univariate analysis of the cox regression model had not shown any of them to be predictors of mortality in the ST only group suggesting that although these three factors were not matched between the two groups, they did not affect survival in patients receiving standard therapy only.

Cotrimoxazole is an inexpensive drug licensed for use in respiratory infections with few serious side effects. They are generally available worldwide, and may have benefit in preventing acute lung injury in this pandemic.²⁹

A randomized control trial with Cotrimoxazole in patients with severe COVID-19 is underway (Clinical Trials Registration-India ID CTRI/2020/10/028297).³⁰

Limitations

Given that this is a case control study, there may be a potential of selection bias. Despite being a retrospective observational study there was excellent data completeness particularly because the patients were closely monitored in a critical care setting. Use of other investigational drugs

as part of ST could have been confounding factors, but due to the significantly large difference in the outcomes and no other investigational drug found to be effective in COVID-19 it is obvious that despite the subtle differences in treatment the impact of co-trimoxazole cannot be overlooked.

Conclusion

If our observation is confirmed by other large scale studies, then hundreds of thousands of lives could be potentially saved worldwide by the use of this inexpensive, widely available and safe drug. In addition reducing hospital stay and use of ventilators could potentially reduce the overwhelming pressure upon the healthcare resources of developing nations. Furthermore this will improve public confidence in the healthcare system and improve and maintain global economy.

Table 1: Baseline characteristics of patients with severe COVID-19 receiving Co-trimoxazole (CTX) with standard therapy or standard therapy alone

	CTX + standard therapy	Standard therapy alone	p-value
Subjects	151	50	
Age (years), mean $\pm$ SD	59 $\pm$ 13	63 $\pm$ 12	0.085
Male, %	81	64	0.015
Body Mass Index	28 $\pm$ 2	27 $\pm$ 2	0.209
Comorbidities, %			
Any disease	88	88	0.988
Diabetes Mellitus	39	60	0.010
Hypertension	60	74	0.080
Dyslipidemia	3	0	0.245
Chronic obstructive pulmonary disease	11	8	0.595
Ischemic Heart Disease	10	8	0.685
Asthma	3	0	0.245
Congestive cardiac failure	1	0	0.413
Chronic kidney disease	3	18	0.000
Interstitial Lung Disease	2	0	0.315
Symptoms			
Duration of illness (days)	4 $\pm$ 2	4 $\pm$ 2	0.843
Breathlessness, %	100	99	0.081
Fever, %	42	40	0.767
Cough, %	56	50	0.439
Chest pain,%	6	0	0.077
Diagnosis			
RT-PCR positive/CT changes, %	79/21	60/40	<0.001
Day 0			
Clinical parameters, mean $\pm$ SD			
Respiratory rate (breaths/min)	31 $\pm$ 5	30 $\pm$ 4	0.137
Body temperature (°F)	99.3 $\pm$ 1.5	99.4 $\pm$ 1.3	0.766
C-Reactive Protein (mg/L)	98 $\pm$ 30	98 $\pm$ 34	0.721
Neutrophil Lymphocyte ratio	10.6 $\pm$ 10.3	9.1 $\pm$ 5	0.604
Ventilatory support			
CPAP / HFNC, %	87/13	85/15	0.245

Definition of abbreviations: SD = standard deviation; CPAP = Continuous Positive Airway Pressure; HFNC = High Flow Nasal Cannula;

Comparison between continuous variables and categorical variables was made by the Mann-Whitney U test and Chi Square test /Fishers exact test respectively. A p-value of <0.05 was considered statistically significant.

Table 2: A) Primary outcomes and B) Observations on Day 0 and Day 2 in patients with severe COVID-19 receiving Co-trimoxazole (CTX) with standard therapy or standard therapy alone

A. Primary Outcomes			
Outcome measures, no. (%)	CTX + standard therapy	Standard therapy alone	p-value
Discharged	132 (87)	30 (60)	<0.001
Died	15 (13)	20 (40)	
Mechanical ventilation	24 (15)	21 (42)	<0.001
Length of critical care stay in days, mean $\pm$ SD	6 $\pm$ 4	11 $\pm$ 7	<0.001
Length of hospital stay in days, mean $\pm$ SD	11 $\pm$ 4	15 $\pm$ 5	<0.001
C-Reactive Protein (mg/L) at day 7	38 $\pm$ 42	62 $\pm$ 46	0.001
B. Observations on Day 0 and Day 7			
CTX + standard therapy (number of cases =151)			
Clinical parameters, mean $\pm$ SD	Day 0	Day 7	p-value
C-Reactive Protein (mg/L)	98 $\pm$ 39	38 $\pm$ 42	<0.001
Neutrophil-Lymphocyte ratio	10.6 $\pm$ 10.2	12 $\pm$ 11.5	<0.001
Standard therapy (number of cases =50)			
Clinical parameters, mean $\pm$ SD	Day 0	Day 7	p-value
C-Reactive Protein (mg/L)	98 $\pm$ 34	62 $\pm$ 46	<0.001
Neutrophil-Lymphocyte ratio	9.1 $\pm$ 5	10.2 $\pm$ 6.2	0.700

Definition of abbreviations: SD = standard deviation;

Comparison between continuous and categorical variables was made by using Wilcoxon Signed Ranks test (for clinical parameters) / Mann-Whitney U test (for length of stay) and Chi Square test /Fishers exact test respectively. A p-value of <0.05 was considered statistically significant.

References

1. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19A Meta-analysis. *JAMA*. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to 150 COVID-19 based on analysis of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46 (5):846-848.
3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall R, Manson J. COVID-19 consider cytokine storm syndromes and Immunosuppression. *Lancet* 2020;395(10229):1033-1034.
4. Giavridis T, van der Stergen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat Med* 2018;24 (6):731-738.
5. Wilcox SR. Management of respiratory failure due to covid-19. *BMJ* 2020;369;m1786.
6. Yap FH, Gomersall CD, Fung KS, et al. Increase in methicillin-resistant *Staphylococcus aureus* acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. *Clin Infect Dis*. 2004;39(4):511-516. doi:10.1086/422641.
7. Jia L, Zhao J, Yang C, et al. Severe Pneumonia Caused by Coinfection with Influenza Virus Followed by Methicillin-Resistant *Staphylococcus aureus* induces Higher Mortality in Mice. *Front Immunol*. 2019;9:3189. Published 2019 Jan 30. doi:10.3389/fimmu.2018.03189
8. National Formulary of India. https://www.nhp.gov.in/national-formulary-of-india_mtl
9. Electronic Medicine Compendium. <https://www.medicines.org.uk/emc/medicine/23909/>
10. Roberts DE, Curd JG. Sulfonamides as antiinflammatory agents in the treatment of wegener's granulomatosis. *Arthritis & Rheumatism*; Vol 33, No.10 (Oct 1990): 1590-1593.
11. Varney VA, Smith B, Quirke G, Parnell H, Rathneepan S, Bansal AS, Nicolas A. P49 The effects of oral cotrimoxazole upon neutrophil and monocyte activation in patients with pulmonary fibrosis and healthy controls; does this relate to its action in idiopathic pulmonary fibrosis? *Thorax* 2017;73(3):A109.
12. Li L, Chen K, Xiang Y, Yoshimura T, Su S, Zhu J, Bian X-W, Wany JM. New Development in Studies of Formyl-Peptide Receptors: Critical Roles in Host Defense. *J Leukoc Biol*. 2016;99(3):425-435.
13. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. Concentration-dependent effects of antimicrobials on *Staphylococcus aureus* toxin-mediated cytokine production from peripheral blood mononuclear cells. *J Antimicrob Chemother*. 2012;67(1):123-129.
14. Vickers IE, Smikle MF. The Immunomodulatory Effect of Antibiotics on the Secretion of Tumour Necrosis Factor Alpha by Peripheral Blood Mononuclear Cells in Response to *Stenotrophomonas maltophilia* Stimulation. *West Indian Med. J*. 2006;55(3):138-141.
15. Richter J, Ng-Sikorski J, Olsson I, Andersson T. Tumor necrosis factor-induced degranulation in adherent human neutrophils is dependent on CD11b/CD18-integrin-triggered oscillations of cytosolic free Ca²⁺. *Proc Natl Acad Sci U S A*. 1990;87(23):9472-9476.

16. Bourke CD et al. Cotrimoxazole Reduces Systemic Inflammation in HIV Infection by Altering the Gut Microbiome and Immune Activation. *Sci Transl Med*.2019; 11(486):eaav0537.
17. Barnes BJ, Adrover JM, Baxter-stoltzfus A, Borczuk A, Cools-Lartigue J. etal. Targeting Potential Drivers of COVID-19: Neutrophil Extracellular Traps. *J. Exp. Med*.2020;217(6):1-7.
18. Moniri A, Marjani M, Tabarsi P, Yadegarynia D, Nadji SA. Health Care Associated Middle East Respiratory Syndrome (MERS): A Case from Iran. *Tanaffos*. 2015;14(4):262-267.
19. Quadery SR et al. Improved Recovery and Survival with Trimethoprim or Cotrimoxazole in Patients with Severe COVID-19: A Retrospective Analysis. *J Viro Res Rep*, 2020; Volume 1(2): 2-6.
20. Choudhari OK et al. Cotrimoxazole as adjuvant therapy in critical ill COVID-19 patients. *Journal of Ideas in Health* 2020;3(Special 1):196-197
21. Al-Kuraishy HM et al. Cotrimoxazole and teicoplanin in the management of Covid-19: Pleiotropic effects, shadows and lights. *Curr Med Drug Res*, 2020, 4 (2), Article ID 210
22. Siddiqui KN et al. Cotrimoxazole in the domiciliary management of patients with severe COVID-19: A case series. *Journal of the Indian Medical Association* · October 2020
23. Government of India Ministry of Health and Family Welfare Directorate General of Health Services (EMR Division). Clinical management protocol: covid-19.
<https://www.mohfw.gov.in/pdf/updatedclinicalmanagementprotocolforcovid19dated03072020.pdf>
24. World Health Organization (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. <https://apps.who.int/iris/handle/10665/332196>. License: CC BY- NC-SA 3.0 IGO
25. Yang A-P, Liu J, Tao W, Li H-M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol*. 2020; 84:106504
26. Adams JY, Rogers AJ, Schuler A, Marelich GP, Fresco JM, Taylor SL, Riedl AW, Baker JM, Escobar GJ, Liu VX. Association Between Peripheral Blood Oxygen Saturation (SpO₂)/Fraction of Inspired Oxygen (FiO₂) Ratio Time at Risk and Hospital Mortality in Mechanically Ventilated Patients. *Perm J*.2020;24(19):113-120.
27. Di Domenico, S.L., Coen, D., Bergamaschi, M. et al. Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-centre retrospective study. *Intern Emerg Med* (2020). <https://doi.org/10.1007/s11739-020-02548-0>
28. Indian Council of Medical Research Department of Health Research New Delhi, India. Treatment Guidelines for Antimicrobial Use in Common Syndromes. 2017.
<http://iamrsn.icmr.org.in/images/pdf/STG270217.pdf>
29. World Health Organization Model List of Essential Medicines. 21st List, 2019.
<https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06>
30. Cotrimoxazole in hospitalised patients with moderate to early-severe COVID-19 infection. Clinical Trials Registry - India ID: CTRI/2020/10/028297.
<http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=48268&EncHid=&userName=CTRI/2020/10/028297>

SUPPLEMENTARY TABLE

Table S1: Cox regression survival analysis for the whole cohort, CTX+ST and ST only groups

Whole cohort		Univariate analysis			Multivariate analysis		
Covariates		HR	95% CI	p-value	HR	95% CI	p-value
Age		1.02	0.99-1.05	0.109			
DM	Ref = absent	2.09	1.03-4.26	0.042			
Asthma	Ref = absent	4.32	0.59-31.71	0.150			
CKD	Ref = absent	8.10	2.49-26.42	0.001	6.29	1.32-29.93	0.021
CAD	Ref = absent	2.08	0.74-5.89	0.166			
BMI		0.88	0.75-1.04	0.136			
CRP day 0		1.02	1.009-1.03	<0.001			
CXR/CT		9.19	3.08-27.44	<0.001			
NLR day 0		1.032	0.99-1.07	0.064			
R/R		1.19	1.12-1.29	<0.001	1.19	1.08-1.31	0.001
Temp		1.28	1.01-1.63	0.041			
CTX+ST group		Univariate analysis			Multivariate analysis		
Covariates		HR	95% CI	p-value	HR	95% CI	p-value
Age		1.06	1.02-1.11	0.009	1.09	1.01-1.185	0.027
DM	Ref = absent	2.41	0.91-6.39	0.078			
Asthma	Ref = absent	7.64	1.01-57.88	0.049	562.67	8.01-39509.33	0.004
CKD	Ref = absent	24.56	2.41-250.42	0.007			
CAD	Ref = absent	2.93	0.82-10.38	0.095			
CRP at day 0		1.03	1.01-1.04	0.001			
NLR at day 0		1.05	1.01-1.09	0.022			
R/R		1.34	1.19-1.50	<0.001	1.37	1.16-1.63	<0.001
ST only group		Univariate analysis			Multivariate analysis		
Covariates		HR	95% CI	p-value	HR	95% CI	p-value
Male sex	Ref = absent	2.29	0.66-7.95	0.191			
Age		0.96	0.91-1.01	0.132			
CRP at day 0		1.02	0.99-1.04	0.088			
CXR/CT		12.73	2.99-54.17	0.001			
R/R		1.20	1.02-1.41	0.028			
Temp		2.61	1.43-4.77	0.002	2.68	1.09-6.54	0.031

Definition of abbreviations: SD = Standard Deviation; CTX = Cotrimoxazole; ST = Standard Therapy; HR = Hazard Ratio; CI = Confidence Interval; DM = Diabetes Mellitus; CKD = Chronic Kidney Disease; CAD = Coronary Artery Disease; BMI = Body Mass Index; CRP = C-reactive protein; NLR = Neutrophil-Lymphocyte ratio; CXR = Chest x-ray; R/R = Respiratory rate; Temp = Temperature